{"entity":{"id":"medicare-negotiation-2026-cancer-drug","kind":"term","name":"Medicare negotiated price for ibrutinib (Imbruvica), first cycle","aka":["IPAY 2026","first cycle of Medicare drug price negotiation","Imbruvica maximum fair price"],"tldr":"The first ten drugs with a Medicare-negotiated price, in effect from 1 January 2026, included one cancer medicine, ibrutinib (Imbruvica). Its price is set per 30-day supply and rose with inflation from 2027.","summary":"United States, under the Inflation Reduction Act's Medicare Drug Price Negotiation Program. CMS's data file of 2 November 2026 lists ten selected drugs for initial price applicability year (IPAY) 2026. Ibrutinib (Imbruvica) is the one cancer medicine among them.\n\nThe file gives Imbruvica a single maximum fair price of $9,319.00 per 30-day equivalent supply for 1 January to 31 December 2026, and $9,571.07 from 1 January 2027 after the inflation adjustment recorded on 25 November 2025. The file also gives a per-unit price for each package (NDC).","asOf":"2026-11-04","links":[{"label":"CMS: Negotiation Program selected drug list and maximum fair price data file, 2 November 2026 (ZIP)","url":"https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip"},{"label":"CMS: Medicare Drug Price Negotiation Program","url":"https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program"}],"tags":["law","us"],"related":["medicare-negotiation-2027-cancer-drugs","medicare-negotiation-2028-cancer-drugs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ibrutinib"],"companies":[],"institutions":[],"pathways":[],"terms":["inflation-reduction-act"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Figures copied from the 'Single MFP per 30 DES' column of the CMS CSV dated 2 November 2026; the dollar amounts are as CMS wrote them."],"category":"Regulation & policy"},"route":"/terms/medicare-negotiation-2026-cancer-drug/","neighbours":{"term":[{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"medicare-negotiation-2028-cancer-drugs","kind":"term","name":"Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib","route":"/terms/medicare-negotiation-2028-cancer-drugs/"},{"id":"medicare-negotiation-2027-cancer-drugs","kind":"term","name":"Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib","route":"/terms/medicare-negotiation-2027-cancer-drugs/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}